Loan Hoang-Sayag
Director/Miembro de la Junta en Orano Med SAS .
Cargos activos de Loan Hoang-Sayag
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Inversor de Capital Privado | 01/11/2018 | - |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | Director/Miembro de la Junta | - | - |
Historial de carrera de Loan Hoang-Sayag
Antiguos cargos conocidos de Loan Hoang-Sayag.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
CELLECTIS S.A. | Director Técnico/Científico/I+D | 08/01/2016 | 05/10/2017 |
MEDIAN TECHNOLOGIES | Director Técnico/Científico/I+D | 26/10/2017 | - |
Quintiles Transnational Corp.
Quintiles Transnational Corp. Miscellaneous Commercial ServicesCommercial Services Quintiles Transnational Corp. provides biopharmaceutical development and commercial outsourcing services. It offers product development and integrated healthcare services, including commercial and observational solutions. The company was founded by Dennis B. Gillings and Gary Koch in September 1990 and is headquartered in Durham, NC. | Director Técnico/Científico/I+D | - | - |
Formación de Loan Hoang-Sayag.
Sorbonne Université | Graduate Degree |
Estadísticas
Internacional
Francia | 6 |
Estados Unidos | 2 |
Operativa
Chief Tech/Sci/R&D Officer | 3 |
Private Equity Investor | 1 |
Graduate Degree | 1 |
Sectorial
Health Technology | 3 |
Commercial Services | 2 |
Health Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
CELLECTIS S.A. | Health Technology |
MEDIAN TECHNOLOGIES | Health Services |
Empresas privadas | 3 |
---|---|
Quintiles Transnational Corp.
Quintiles Transnational Corp. Miscellaneous Commercial ServicesCommercial Services Quintiles Transnational Corp. provides biopharmaceutical development and commercial outsourcing services. It offers product development and integrated healthcare services, including commercial and observational solutions. The company was founded by Dennis B. Gillings and Gary Koch in September 1990 and is headquartered in Durham, NC. | Commercial Services |
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Finance |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | Health Technology |
- Bolsa de valores
- Insiders
- Loan Hoang-Sayag
- Experiencia